title: Low-dose continuous infusion of factor VIII in patients with haemophilia A.
abstract: Patients with haemophilia A (HA) or B (HB) can be given prophylactic or on-demand treatment administered by continuous infusion or bolus injections of factor VIII (FVIII) or IX (FIX). In this study we evaluated the efficacy and safety of low-dose continuous infusion of FVIII or FIX.
  
  
  
  We studied all eligible patients with HA or HB treated with continuous infusion of factor concentrates over an 18-year period in a single Slovenian Haemophilia Comprehensive Care Centre. Treatment started with a bolus injection of FVIII or FIX, followed by continuous infusion at the initial rate of 2 IU/kg/h of FVIII in HA patients and 4.5 IU/kg/h of FIX in HB patients. The infusion rate was subsequently adjusted according to the indication for therapy.
  
  
  
  A total of 66 continuous infusions (40 in major surgery, 10 in minor surgery and 16 with bleeding episode) in 46 HA patients and 16 (15 in severe and 1 in mild HA) in eight HB patients were included in the study. During the first week of treatment, the median continuous infusion rates in HA patients undergoing major surgery, minor surgery and a bleeding event were 2.18 (0.75-3.68), 1.48 (1.0-2.54) and 2.24 (1.33-3.93) IU/kg/h, respectively. The median FVIII activities were 0.69 (0.37-1.19), 0.47 (0.39-0.84) and 0.52 (0.36-1.06) IU/mL. After the first week of treatment, even lower doses of FVIII were needed. Red blood cell transfusions had to be administered to three patients (2 with severe and 1 with moderate HA) during the continuous infusion and inhibitors developed in five patients. In HB patients, the median continuous infusion rate was 1.85 (1.07-2.94) IU/kg/h and the median FIX activity was 0.62 (0.30-1.04) IU/mL. Red blood cell transfusions were not required, and thrombophlebitis and inhibitors did not appear.
  
  
  
  Overall, low-dose continuous infusion was shown to be an effective and safe way of treating patients with HA. The protocol used also proved efficient and safe in all HB patients.
authors.affiliation: Haematology and Oncology Unit, University Children's Hospital, University Medical Centre, Ljubljana, Slovenia.
authors.forename: Tomaž
authors.initials: T
authors.lastname: Prelog
authors.affiliation: Haematology and Oncology Unit, University Children's Hospital, University Medical Centre, Ljubljana, Slovenia.
authors.forename: Majda Benedik
authors.initials: MB
authors.lastname: Dolničar
authors.affiliation: Haematology and Oncology Unit, University Children's Hospital, University Medical Centre, Ljubljana, Slovenia.
authors.forename: Lidija
authors.initials: L
authors.lastname: Kitanovski
mesh_terms: D005169:Factor VIII / Q000008:administration & dosage; D006467:Hemophilia A / Q000097:blood*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D016896:Treatment Outcome
chemical_list: D005169:Factor VIII